-+ 0.00%
-+ 0.00%
-+ 0.00%

South Korea Rejects Raphas' Phase 2b/3 Trial Application for Allergy Drug DF19001

PUBT·11/20/2026 10:23:02
South Korea Rejects Raphas' Phase 2b/3 Trial Application for Allergy Drug DF19001
  • Raphas received South Korea's regulatory rejection of its Phase 2b/3 trial application for allergic rhinitis treatment DF19001 on Nov. 20, 2026.
  • The planned 52-week study would evaluate efficacy and safety in patients with house dust mite allergic rhinitis.
  • Regulators requested revisions to the trial protocol and additional manufacturing and quality documentation.
  • The rejection did not concern Phase 1 safety or immunogenicity findings, whose results were previously disclosed on Dec. 17, 2025.
  • The company plans to address the deficiencies through regulatory consultations before resubmitting its application promptly.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raphas Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261120900961), on November 20, 2026, and is solely responsible for the information contained therein.